Literature DB >> 10530702

Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization.

L G McNatt1, L Weimer, J Yanni, A F Clark.   

Abstract

Ocular neovascular diseases represent a major cause of blindness in the world. Angiostatic steroids are a unique class of compounds which inhibit the formation of new blood vessels in various models, including ocular models of angiogenesis. In search of potent new anti-angiogenic agents for the treatment of ocular neovascular disease, a large group of steroids were evaluated for angiostatic activity in the chick embryo CAM model. Angiostatic activity was found among all steroid classes included in the study. There was a good correlation between the angiostatic efficacies of 15 diverse steroids tested in the chick CAM and in the rabbit LPS-induced corneal pocket models of neovascularization (r=0.76, p=0.01). These studies show that potent angiostatic steroids inhibit neovascularization in two different animal models, suggesting a common mechanism of action. Glucocorticoid therapy is sometimes associated with ocular side effects. Two of the most potent angiostatic steroids, AL-3789 and AL-4940, were evaluated for glucocorticoid-mediated antiinflammatory activity in the in vitro U937 cell model of LPS-induced IL-1 induction and found to be devoid of glucocorticoid activity. Angiostatic steroids which lack glucocorticoid activity should be attractive drug candidates for treating ocular neovascular disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10530702     DOI: 10.1089/jop.1999.15.413

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  14 in total

1.  A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis.

Authors:  W Kenneth Ward
Journal:  J Diabetes Sci Technol       Date:  2008-09

Review 2.  Clinical correlates of common corneal neovascular diseases: a literature review.

Authors:  Nizar Saleh Abdelfattah; Mohamed Amgad; Amira A Zayed; Hamdy Salem; Ahmed E Elkhanany; Heba Hussein; Nawal Abd El-Baky
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

Review 3.  Current and future treatment options for nonexudative and exudative age-related macular degeneration.

Authors:  Grant M Comer; Thomas A Ciulla; Mark H Criswell; Michael Tolentino
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes.

Authors:  Sandeep Kumar; Shaily Shah; Emily Rose Deutsch; Hai Michael Tang; John Danias
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

5.  VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.

Authors:  Erica K M Reeves; Eric P Hoffman; Kanneboyina Nagaraju; Jesse M Damsker; John M McCall
Journal:  Bioorg Med Chem       Date:  2013-02-18       Impact factor: 3.641

Review 6.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

7.  Contrast-enhanced power Doppler sonography of knee synovitis in rheumatoid arthritis: assessment of therapeutic response.

Authors:  F Salaffi; M Carotti; P Manganelli; E Filippucci; G M Giuseppetti; W Grassi
Journal:  Clin Rheumatol       Date:  2004-05-15       Impact factor: 2.980

8.  Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration.

Authors:  Albert J Augustin; Donald J D'Amico; William F Mieler; Cary Schneebaum; Cliff Beasley
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-28       Impact factor: 3.117

9.  Regression of aggressive corneal vascularization after photodynamic therapy, subconjunctival Avastin injections and topical cyclosporin-A 1% drops: A case report.

Authors:  Omar M Kirat; Hassan A Al-Dhibi
Journal:  Saudi J Ophthalmol       Date:  2010-05-27

10.  Treatment of steroid-induced elevated intraocular pressure with anecortave acetate: a randomized clinical trial.

Authors:  Ingeborg Stalmans; David G Callanan; Monte S Dirks; Marlene R Moster; Alan L Robin; Joachim Van Calster; Sally A Scheib; Jaime E Dickerson; Theresa A Landry; Michael V W Bergamini
Journal:  J Ocul Pharmacol Ther       Date:  2012-08-03       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.